Stereoselective interactions of peptide inhibitors with the β-amyloid peptide

被引:138
作者
Chalifour, RJ [1 ]
McLaughlin, RW [1 ]
Lavoie, L [1 ]
Morissette, C [1 ]
Tremblay, N [1 ]
Boulé, M [1 ]
Sarazin, P [1 ]
Stéa, D [1 ]
Lacombe, D [1 ]
Tremblay, P [1 ]
Gervais, F [1 ]
机构
[1] Neurochem Inc, St Laurent, PQ H4S 2A1, Canada
关键词
D O I
10.1074/jbc.M212694200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Residues 16 - 20 of the beta-amyloid peptide (Abeta) function as a self-recognition element during Abeta assembly into fibers. Peptides containing this motif retain the ability to interact with Abeta and, in some cases, potently inhibit its assembly. Replacing L- with D-amino acids could stabilize such peptides and permit their evaluation as therapeutic agents for Alzheimer's disease. Here we have assessed the effect that such a chiral reversal has on inhibitory potency. D-enantiomers of five peptides, KLVFFA, KKLVFFA, KFVFFA, KIVFFA, and KVVFFA, were unexpectedly more active as inhibitors in an in vitro fibrillogenesis assay. Circular dichroism showed that D-KLVFFA more effectively prevented Abeta adopting the beta-sheet secondary structure correlated with fibrillogenesis. Electron microscopy showed that fiber formation was also more strongly inhibited by D-KLVFFA. Heterochiral inhibition was confirmed using D-Abeta, on the principle that enantiomeric proteins exhibit reciprocal chiral biochemical interactions. With D-Abeta, L-KLVFFA was the more potent inhibitor, rather than D-KLVFFA. Most significantly, D-peptides were more potent at reducing the toxicity of both Abeta(1-40) and Abeta(1-42) toward neuronal cells in culture. This unforeseen heterochiral stereoselectivity of Abeta for D-peptide inhibitors should be considered during future design of peptide-based inhibitors of Abeta neurotoxicity and fibrillogenesis.
引用
收藏
页码:34874 / 34881
页数:8
相关论文
共 39 条
[1]   Characterization of copper interactions with Alzheimer amyloid β peptides:: Identification of an attomolar-affinity copper binding site on amyloid β1-42 [J].
Atwood, CS ;
Scarpa, RC ;
Huang, XD ;
Moir, RD ;
Jones, WD ;
Fairlie, DP ;
Tanzi, RE ;
Bush, AI .
JOURNAL OF NEUROCHEMISTRY, 2000, 75 (03) :1219-1233
[2]  
Colón W, 1999, METHOD ENZYMOL, V309, P605
[3]  
CORIGLIANOMURPHY MA, 1985, INT J PEPT PROT RES, V25, P225
[4]   Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence [J].
Esler, WP ;
Stimson, ER ;
Ghilardi, JR ;
Lu, YA ;
Felix, AM ;
Vinters, HV ;
Mantyh, PW ;
Lee, JP ;
Maggio, JE .
BIOCHEMISTRY, 1996, 35 (44) :13914-13921
[5]  
Esler WP, 1999, BIOPOLYMERS, V49, P505, DOI 10.1002/(SICI)1097-0282(199905)49:6<505::AID-BIP8>3.3.CO
[6]  
2-9
[7]   D-peptide ligands for the co-chaperone DnaJ [J].
Feifel, B ;
Schonfeld, HJ ;
Christen, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (20) :11999-12002
[8]   Modified-peptide inhibitors of amyloid β-peptide polymerization [J].
Findeis, MA ;
Musso, GM ;
Arico-Muendel, CC ;
Benjamin, HW ;
Hundal, AM ;
Lee, JJ ;
Chin, J ;
Kelley, M ;
Wakefield, J ;
Hayward, NJ ;
Molineaux, SM .
BIOCHEMISTRY, 1999, 38 (21) :6791-6800
[9]   A strategy for designing inhibitors of beta-amyloid toxicity [J].
Ghanta, J ;
Shen, CL ;
Kiessling, LL ;
Murphy, RM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (47) :29525-29528
[10]   ALZHEIMERS-DISEASE - INITIAL REPORT OF THE PURIFICATION AND CHARACTERIZATION OF A NOVEL CEREBROVASCULAR AMYLOID PROTEIN [J].
GLENNER, GG ;
WONG, CW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 120 (03) :885-890